What happened with STXS today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Stereotaxis makes equipment that lets physicians use computer-controlled magnetic fields to steer catheter tips through blood vessels and heart chambers. Its main clinical use is cardiac ablation, which treats abnormal heart rhythms. Genesis and GenesisX are its principal robotic navigation systems, used alongside compatible imaging equipment and catheters.
Hospitals pay upfront for equipment and installation, then pay for disposable instruments used in procedures, service after the warranty period and software updates. Disposable devices, service and accessories together generate most revenue, rather than system sales. The business therefore depends on hospitals installing systems and physicians using them regularly, not just buying the equipment.
Compatible imaging, mapping systems and catheters supplied through partners are essential to making the equipment usable. Biosense Webster, a Johnson & Johnson subsidiary, previously supplied the ablation catheters predominantly used with the systems. Its supply obligation has ended, and continued availability was uncertain while Stereotaxis ramped up its replacement MAGiC catheter. MAGiC has European clearance and U.S. approval, but many customers still depended on Biosense Webster supply during that transition. Other disposable devices need the applicable regulatory clearance or approval before Stereotaxis can market them in the United States.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Stereotaxis’s results hinge on hospitals adopting robotic ablation, completing lengthy installations and keeping compatible catheters available as its own MAGiC production ramps up, making Johnson & Johnson’s supply decisions important to watch.
Johnson & Johnson’s Biosense Webster both competes for hospitals’ ablation business and supplied the compatible catheters historically used with Stereotaxis’s robots. Watch whether it continues supplying those catheters: continued supply is uncertain as Stereotaxis ramps up its own MAGiC production.
Medtronic competes with Stereotaxis for electrophysiologists’ choice of how to treat heart rhythm disorders, selling cryoablation and pulsed-field ablation systems rather than Stereotaxis’s robotic platform. Adoption of those systems is worth watching as Stereotaxis tries to persuade hospitals and physicians to switch to robotic ablation.
Stereotaxis, Inc. earningsThis company
Stereotaxis's report will show whether hospitals are buying its robotic navigation systems and whether installed systems are bringing in more catheter, service and software revenue.
Read system sales alongside disposable, service and accessories revenue. Growth in both would mean new hospitals are installing systems and existing customers are continuing to use them. Weak system sales would point to slower hospital investment; recurring revenue that fails to grow would suggest the installed base is generating fewer repeat sales.
Medtronic plc earningsMDT
Medtronic's report will show how hospitals are adopting its ablation systems, a measure of how strongly it competes with Stereotaxis for patients and hospital budgets.
Look for reported sales or adoption trends in Medtronic’s cryoablation and pulsed-field ablation systems. Stronger adoption means hospitals and physicians are choosing treatments that compete with Stereotaxis’s robotic approach, making system purchases and procedures harder for Stereotaxis to win. Weaker adoption eases evidence of that competitive pull, but does not show that hospitals will choose Stereotaxis instead.
